Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated
by the immune system. Systemic therapy is used in the advanced stage and until 2017 …

Abstract mRNA vaccines have emerged as a revolutionary tool to generate rapid and
precise immune responses against infectious diseases and cancers. Compared with …

Background Extensive-stage small-cell lung cancer (ES-SCLC) is associated with poor
prognosis and treatment options are scarce. Immunotherapy has shown robust clinical …

Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

Abstract PD-1 blockade unleashes CD8 T cells, including those specific for mutation-
associated neoantigens (MANA), but factors in the tumour microenvironment can inhibit …

Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

Conventional chemotherapeutics have been developed into clinically useful agents based
on their ability to preferentially kill malignant cells, generally owing to their elevated …

In recent years, breakthroughs have been made in tumor immunotherapy. However, tumor
immunotherapy, particularly anti-PD-1/PD-L1 immune checkpoint inhibitors, is effective in …

An effective tumor vaccine vector that can rapidly display neoantigens is urgently needed.
Outer membrane vesicles (OMVs) can strongly activate the innate immune system and are …

Cancer metastases and recurrence after surgical resection remain an important cause of
treatment failure. Here we demonstrate a general strategy to fabricate personalized …